<DOC>
	<DOCNO>NCT01848730</DOCNO>
	<brief_summary>To investigate effect repeat oral dose CNV2197944 75 mg tid pain experience post-herpetic neuralgia ( PHN ) measure change PI-NRS three week treatment compare baseline period .</brief_summary>
	<brief_title>Efficacy Safety CNV2197944 Versus Placebo Patients With Post-herpetic Neuralgia</brief_title>
	<detailed_description>A 3 week randomise crossover study investigate effect repeat oral dose CNV2197944 75 mg tid versus placebo pain experience post-herpetic neuralgia ( PHN . Each 3 week treatment period seperated 2 week washout period . The primary outcome measure change baseline PI-NRS three week treatment . Secondary outcome measure include pain responder rate , clinical patient global impression pain , Neuropathic Pain Symptom Inventory .</detailed_description>
	<mesh_term>Neuralgia</mesh_term>
	<mesh_term>Neuralgia , Postherpetic</mesh_term>
	<criteria>Male female 18 85 year age inclusive , time signing informed consent . Patients postherpetic neuralgia ( PHN ) pain screen present 3 month heal herpes zoster skin rash . The maximum duration PHN longer 5 year . Patients severe pain , may impair selfassessment pain due PHN . Patients receive nerve block neuropathic pain within 4 week prior start singleblind placebo runin Certain medication use relieve pain PHN , specifically gabapentinoids ( gabapentin pregabalin ) , carbamazepine topical agent ( eg capsaicin , lidocaine ) Patients documented failure respond maximally tolerate dose regimen gabapentin pregabalin . Patients take one medication treat PHN pain</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>January 2014</verification_date>
</DOC>